|
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
|
 |
 |
|
|
|
|
|
|
|
|
||||||||
 |
|
|
FOR IMMEDIATE RELEASE03/29/2005 Contact: American Regent, Inc. A Division of Luitpold Pharmaceuticals, Inc. Walter Tozzi, R.Ph., M.S., M.B.A. Director of Marketing and Professional Services 631-924-4000 wtozzi@americanregent.com Shirley, NY – March 29, 2005: American Regent, Inc. announces the launch of its new injectable product, Calcitriol Injection.
The HCPCS code for Calcitriol Injection is J0636. Calcitriol Injection is “AP” rated and indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. About American Regent, Inc. Headquartered in Shirley, NY, the company manufactures and distributes over 65 pharmaceutical products including Venofer® (iron sucrose injection, USP), the #1 selling IV iron therapy in the U.S. For more information about this product, or other American Regent products, please contact our customer service department at 1-800-645-1706. Source: American Regent, Inc. |
|
|||||||||
|
|||||||||||||
|
|
|
|
|
|||